View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
April 3, 2019updated 12 Jul 2022 1:07pm

Inovio closes enrolment in Phase I/II glioblastoma trial

Inovio Pharmaceuticals has completed enrolment in a Phase I/II clinical trial of a INO-5401 combination to treat patients with newly diagnosed glioblastoma (GBM).

Inovio Pharmaceuticals has completed enrolment in a Phase I/II clinical trial of a INO-5401 combination to treat patients with newly diagnosed glioblastoma (GBM).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial involves a combination of INO-5401, INO-9012 and cemiplimab-rwlc (Libtayo or REGN2810).

INO-5401 is a T cell activating immunotherapy designed to encode various antigens expressed by GBM, while INO-9012 is an immune activator encoding IL-12.

Cemiplimab-rwlc is a PD-1 inhibitor co-developed by Regeneron Pharmaceuticals and Sanofi.

The open-label, multi-centre Phase I/II trial will assess the safety, immunogenicity and preliminary efficacy of the combination in 52 participants.

“This is an important step for Inovio’s cancer combination strategy using our T cell-generating therapies in combination with PD-1/PD-L1 inhibitors.”

INO-5401 and INO-9012 will be administered intramuscularly after electroporation (EP) in combination with cemiplimab and chemoradiation and radiation.

The primary outcome measure of the trial is the proportion of subjects with adverse events, while secondary outcomes include overall survival and a change in antigen-specific humoral response from baseline.

Interim data is expected to be available by the end of this year, and the trial is set to be completed in January 2021.

Inovio Pharmaceuticals president and CEO Joseph Kim said: “This is an important step for Inovio’s cancer combination strategy using our T cell-generating therapies in combination with PD-1/PD-L1 inhibitors for GBM and for multiple other cancers to improve overall efficacy of immunotherapy.

“In this GBM trial, our goal is to increase the overall survival of patients facing a disease where neither the standard of care, nor clinical outcomes have changed in a clinically significant way in more than a decade.”

Glioblastoma is an aggressive form of brain cancer. Patients on standard of care are said to have a median overall survival of approximately 15 months, with the average five-year survival rate being less than 5%.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena